Cancer Cachexia and Cancer Wasting

Cancer cachexia is a multifactorial syndrome of ongoing loss of skeletal muscle mass, with or without loss of fat mass, that cannot be fully reversed by conventional nutritional support and that leads to progressive functional impairment. It is distinguished from simple starvation or weight loss because it is driven by tumour metabolism and systemic inflammation rather than by reduced intake alone.

Definition

Cancer cachexia is a multifactorial syndrome defined by an ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment, conventionally identified by weight loss thresholds, low body mass index with weight loss, or low muscularity with weight loss.

Scope

The topic covers the consensus definition and staging of cancer cachexia, the metabolic and inflammatory mechanisms that drive muscle wasting, how the syndrome is assessed, and why it responds incompletely to nutrition alone. It is presented as a reference concept within oncology nutrition and does not provide individualized treatment or pharmacologic instructions.

Core questions

• What distinguishes cancer cachexia from simple weight loss or starvation?
• How is cachexia defined, staged, and assessed in practice?
• Why does nutritional support alone fail to fully reverse the syndrome?

Key concepts

• Skeletal muscle wasting
• Systemic inflammation
• Anorexia and reduced intake
• Precachexia, cachexia, and refractory cachexia stages
• Sarcopenia and low muscularity
• Anabolic resistance

Mechanisms

Cachexia arises from the interaction of reduced food intake (anorexia) with abnormal metabolism driven by the tumour and the host inflammatory response. Pro-inflammatory mediators and tumour-derived factors promote net protein breakdown in skeletal muscle, increase resting energy expenditure in some patients, and impair the normal anabolic response to feeding (anabolic resistance). Because the catabolic drive persists independent of intake, simply supplying more calories and protein does not, by itself, restore lost muscle, which is why the consensus defines cachexia partly by its incomplete response to conventional nutritional support.

Clinical relevance

Cachexia is associated with reduced tolerance of anticancer treatment, impaired physical function and quality of life, and worse survival, and its recognition prompts earlier and multimodal supportive care. This entry describes the syndrome for educational reference; decisions about nutritional, pharmacologic, or exercise interventions belong to the treating multidisciplinary team and are individualized.

Epidemiology

Cachexia is common in advanced cancer and is most frequent in tumours of the upper gastrointestinal tract, pancreas, and lung; weight loss is present in a large proportion of patients at diagnosis in these cancers. It contributes substantially to morbidity and is implicated in a meaningful share of cancer deaths, though estimates vary with the population and definition used.

Evidence & guidelines

The international consensus (Fearon et al., 2011) provides the widely used definition and staging framework, and the ASCO guideline on management of cancer cachexia (Roeland et al., 2020) summarizes the evidence base, noting the limited efficacy of available interventions. ESPEN guidance (Arends et al., 2017) situates cachexia within broader oncology nutrition, and the Nature Reviews Disease Primers review (Baracos et al., 2018) synthesizes the underlying biology.

History

Wasting in advanced disease has been described since antiquity, but the modern framing of cancer cachexia as a distinct, inflammation-driven metabolic syndrome was consolidated in the late twentieth and early twenty-first centuries. The 2011 international consensus marked a turning point by offering an operational definition and a staging model (precachexia, cachexia, refractory cachexia), which standardized research and clinical recognition.

Debates

Can cancer cachexia be reversed, and by what means?

The consensus holds that established cachexia cannot be fully reversed by conventional nutrition alone, which has driven interest in multimodal approaches combining nutrition, exercise, and anti-inflammatory or anabolic agents; the optimal strategy and which patients benefit remain unsettled.

Key figures

• Kenneth Fearon
• Vickie Baracos
• Eric Roeland
• Egidio del Fabbro

Seminal works

• fearon-2011-consensus
• baracos-2018-cachexia
• roeland-2020-asco

Frequently asked questions

Is cancer cachexia the same as malnutrition?

No. Malnutrition is a broad term for deficits in intake or nutrient status, while cachexia is a specific inflammation- and tumour-driven syndrome of muscle loss that persists despite adequate feeding; a person can be malnourished without being cachectic and vice versa.

If feeding cannot fully reverse cachexia, why is nutrition still part of care?

Nutritional support can slow loss, support function, and address the intake deficit that coexists with the metabolic abnormality, and it is typically combined with other measures rather than expected to reverse established cachexia on its own.